Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration

How can DNA methylation clocks, histone modification patterns, and epigenetic age acceleration serve as biomarkers for Alzheimer disease, Parkinson disease, and related neurodegenerative conditions? Focus areas: 1. Diagnostic biomarker utility: Can epigenetic clocks distinguish AD from other dementias? What is the sensitivity/specificity? 2. Prognostic value: Does epigenetic age acceleration correlate with disease progression, cognitive decline rate, or conversion from MCI to AD? 3. Biomarker validation: What blood, CSF, or tissue samples are available for validation? Which clock algorithms (Horvath, Hannum, PhenoAge, GrimAge) perform best? 4. Mechanistic links: How do epigenetic changes relate to tau pathology, amyloid burden, alpha-synuclein, TDP-43, and other neurodegenerative hallmarks? 5. Confounding factors: How do comorbidities (vascular disease, diabetes), lifestyle, and cell type composition affect epigenetic biomarker readings? The existing gap on therapeutic approaches (gap-v2-bc5f270e) addressed epigenetic clock modulation as therapy. This gap focuses specifically on biomarker development and validation for diagnosis, prognosis, and disease monitoring.